BR112014020043A2 - anticorpos endotelina-1-antigrande (et-1-grande) e usos dos mesmos - Google Patents

anticorpos endotelina-1-antigrande (et-1-grande) e usos dos mesmos

Info

Publication number
BR112014020043A2
BR112014020043A2 BR112014020043A BR112014020043A BR112014020043A2 BR 112014020043 A2 BR112014020043 A2 BR 112014020043A2 BR 112014020043 A BR112014020043 A BR 112014020043A BR 112014020043 A BR112014020043 A BR 112014020043A BR 112014020043 A2 BR112014020043 A2 BR 112014020043A2
Authority
BR
Brazil
Prior art keywords
antibodies
endothelin
disorders
bind
ece
Prior art date
Application number
BR112014020043A
Other languages
English (en)
Inventor
Macdonald Douglas
C Morton Lori
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112014020043A2 publication Critical patent/BR112014020043A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)

Abstract

resumo patente de invenção: "anticorpos endotelina-1- antigrande (et-1-grande) e usos dos mesmos". a presente invenção proporciona anticorpos que se ligam a endotelina-1-grande ("et-1-grande"), e métodos de uso dos mesmos. de acordo com certas concretizações da invenção, os anticorpos especificamente se ligam a et-1-grande humana, mas não se ligam a et-1-pequena humana (isto é, a forma ativa de endotelina-1 que resulta de clivagem proteolítica de et-1-grande por enzima-1 de conversão de endotelina [ece-1]). de acordo com certas concretizações da invenção, os anticorpos et-1- antigrandes são capazes de bloquear clivagem de et-1-grande por ece-1. os anticorpos da invenção são úteis para o tratamento de distúrbios relacionados a et-1-grande, incluindo distúrbios de hipertensão, distúrbios fibróticos, distúrbios neurodegenerativos, distúrbios da retina, dor e cânceres.
BR112014020043A 2012-02-22 2013-02-22 anticorpos endotelina-1-antigrande (et-1-grande) e usos dos mesmos BR112014020043A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601622P 2012-02-22 2012-02-22
US201261677024P 2012-07-30 2012-07-30
PCT/US2013/027380 WO2013126740A1 (en) 2012-02-22 2013-02-22 Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112014020043A2 true BR112014020043A2 (pt) 2017-07-04

Family

ID=47790543

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014020043A BR112014020043A2 (pt) 2012-02-22 2013-02-22 anticorpos endotelina-1-antigrande (et-1-grande) e usos dos mesmos

Country Status (23)

Country Link
US (1) US9751932B2 (pt)
EP (1) EP2817336A1 (pt)
JP (1) JP2015509946A (pt)
KR (1) KR20140130713A (pt)
CN (1) CN104203980B (pt)
AR (1) AR090128A1 (pt)
AU (1) AU2013222203B2 (pt)
BR (1) BR112014020043A2 (pt)
CA (1) CA2864830A1 (pt)
CL (1) CL2014002232A1 (pt)
CO (1) CO7071097A2 (pt)
EA (1) EA201491562A1 (pt)
HK (1) HK1205523A1 (pt)
IL (1) IL233781A0 (pt)
MX (1) MX2014010060A (pt)
MY (1) MY169210A (pt)
NZ (1) NZ629553A (pt)
PH (1) PH12014501730B1 (pt)
SG (2) SG10201606802PA (pt)
TW (1) TWI613215B (pt)
UY (1) UY34637A (pt)
WO (1) WO2013126740A1 (pt)
ZA (1) ZA201405554B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086149A1 (en) 2006-04-04 2007-10-11 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
US9719981B2 (en) * 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
WO2015057906A1 (en) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists
CN116726183A (zh) 2015-08-03 2023-09-12 Enb治疗公司 用于治疗与etbr激活相关的癌症的组合物和方法
WO2017049038A2 (en) * 2015-09-16 2017-03-23 Ablexis, Llc Anti-cd115 antibodies
CN108341877B (zh) * 2017-01-23 2021-04-30 吴剑波 一种抗活化凝血因子v单克隆抗体及其制备方法和用途
KR20200119246A (ko) 2018-01-12 2020-10-19 이엔비 테라퓨틱스, 인크. Etbr 활성화와 관련된 암을 치료하기 위한 중수소화 화합물, 조성물, 및 방법
KR20210022650A (ko) * 2018-06-19 2021-03-03 리제너론 파아마슈티컬스, 인크. 항-인자 XII/XIIa 항체 및 이의 용도
AU2020296105A1 (en) * 2019-06-21 2022-02-03 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital Neutralizing antibodies to human endothelin
US20240011986A1 (en) * 2020-11-06 2024-01-11 The Regents Of The University Of Colorado, A Body Corporate Bacterial biomarker for rheumatoid arthritis and related materials and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0331100A1 (en) 1988-03-02 1989-09-06 Takeda Chemical Industries, Ltd. Anti-endothelin antibodies and their use
CA2008122A1 (en) 1989-01-26 1990-07-26 Tetsuro Okabe Pharmaceutical composition for diseases caused by vasoconstriction
JP3017773B2 (ja) * 1989-06-22 2000-03-13 塩野義製薬株式会社 エンドセリン認識モノクローナル抗体、該抗体産生ハイブリドーマおよび該抗体を用いるエンドセリンのラジオイムノアッセイ
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008130704A2 (en) 2007-04-17 2008-10-30 Imclone Llc PDGFRβ-SPECIFIC INHIBITORS
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CA2797033C (en) * 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途

Also Published As

Publication number Publication date
WO2013126740A1 (en) 2013-08-29
CA2864830A1 (en) 2013-08-29
AU2013222203B2 (en) 2017-12-07
CN104203980B (zh) 2018-01-12
PH12014501730A1 (en) 2014-11-10
MX2014010060A (es) 2014-09-22
CN104203980A (zh) 2014-12-10
AR090128A1 (es) 2014-10-22
US20130216547A1 (en) 2013-08-22
US9751932B2 (en) 2017-09-05
TW201348255A (zh) 2013-12-01
ZA201405554B (en) 2015-12-23
EA201491562A1 (ru) 2014-12-30
TWI613215B (zh) 2018-02-01
MY169210A (en) 2019-03-18
SG11201404487SA (en) 2014-10-30
UY34637A (es) 2013-05-31
NZ629553A (en) 2016-10-28
HK1205523A1 (en) 2015-12-18
AU2013222203A1 (en) 2014-09-18
SG10201606802PA (en) 2016-10-28
EP2817336A1 (en) 2014-12-31
CO7071097A2 (es) 2014-09-30
IL233781A0 (en) 2014-09-30
PH12014501730B1 (en) 2014-11-10
JP2015509946A (ja) 2015-04-02
KR20140130713A (ko) 2014-11-11
CL2014002232A1 (es) 2015-01-16

Similar Documents

Publication Publication Date Title
BR112014020043A2 (pt) anticorpos endotelina-1-antigrande (et-1-grande) e usos dos mesmos
CY1123404T1 (el) Αντι-girt αντισωματα
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1122060T1 (el) Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
BR112014020826A2 (pt) moduladores e métodos de uso
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
MX2015010749A (es) Anticuerpos humanos para nav1.7.
BR112014018471A2 (pt) anticorpos anti-ige m1' e métodos para o seu uso
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
GT201200318A (es) Anticuerpos hacia gdf8 humano
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
BR112013016935A2 (pt) modulação da dineína na pele
BR112014032728A2 (pt) uso de marcadores no diagnóstico e tratamento de câncer de próstata
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
BR112018012749A2 (pt) composições para higiene pessoal
BR112013018264A2 (pt) "peptídeos sintéticos, uso dos mesmos e composição farmacêutica"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2554 DE 17/12/2019.